Annual report

Period2024-01-21 → 2025-01-20

Filed2025-04-16

StandardJapan GAAP

ConsolidatedYes

Data checks24 of 24 passed

Key figures · 148

Metric	Value	Period	Scope	Source row
Revenue	¥237.2bn	2024-01-21 → 2025-01-20	Cons.	Net sales
Revenue	¥213.4bn	2023-01-21 → 2024-01-20	Cons.	Net sales
Revenue	¥160.1bn	2022-01-21 → 2023-01-20^d	Cons.	Net sales (5-year summary)
Revenue	¥162.6bn	2021-01-21 → 2022-01-20^d	Cons.	Net sales (5-year summary)
Revenue	¥158.2bn	2020-01-21 → 2021-01-20^d	Cons.	Net sales (5-year summary)
Operating income	¥4.8bn	2024-01-21 → 2025-01-20	Cons.	Operating income
Operating income	¥3.7bn	2023-01-21 → 2024-01-20	Cons.	Operating income
Ordinary income	¥3.0bn	2024-01-21 → 2025-01-20	Cons.	Ordinary income
Ordinary income	¥3.1bn	2023-01-21 → 2024-01-20	Cons.	Ordinary income
Ordinary income	¥591m	2022-01-21 → 2023-01-20^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥5.7bn	2021-01-21 → 2022-01-20^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥5.7bn	2020-01-21 → 2021-01-20^d	Cons.	Ordinary income loss (5-year summary)
Profit before tax	¥7.9bn	2024-01-21 → 2025-01-20	Cons.	Income before income taxes
Profit before tax	¥5.6bn	2023-01-21 → 2024-01-20	Cons.	Income before income taxes
Net income (owners)	¥3.8bn	2024-01-21 → 2025-01-20	Cons.	Profit loss attributable to owners of parent
Net income (owners)	¥4.4bn	2023-01-21 → 2024-01-20	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥507m	2022-01-21 → 2023-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥4.0bn	2021-01-21 → 2022-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥3.2bn	2020-01-21 → 2021-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income	¥3.4bn	2024-01-21 → 2025-01-20	Cons.	Profit loss
Net income	¥4.6bn	2023-01-21 → 2024-01-20	Cons.	Profit loss
Total assets	¥185.2bn	at 2025-01-20	Cons.	Assets
Total assets	¥177.6bn	at 2024-01-20	Cons.	Assets
Total assets	¥164.2bn	at 2023-01-20^d	Cons.	Total assets (5-year summary)
Total assets	¥159.0bn	at 2022-01-20^d	Cons.	Total assets (5-year summary)
Total assets	¥157.6bn	at 2021-01-20^d	Cons.	Total assets (5-year summary)
Total liabilities	¥91.7bn	at 2025-01-20	Cons.	Liabilities
Total liabilities	¥86.1bn	at 2024-01-20	Cons.	Liabilities
Net assets / equity	¥93.5bn	at 2025-01-20	Cons.	Net assets
Net assets / equity	¥91.5bn	at 2024-01-20	Cons.	Net assets
Net assets / equity	¥84.1bn	at 2023-01-20^d	Cons.	Net assets
Net assets / equity	¥83.3bn	at 2022-01-20^d	Cons.	Net assets (5-year summary)
Net assets / equity	¥82.6bn	at 2021-01-20^d	Cons.	Net assets (5-year summary)
Cash and deposits	¥30.7bn	at 2025-01-20	Cons.	Cash and deposits
Cash and deposits	¥32.4bn	at 2024-01-20	Cons.	Cash and deposits
Cash & equivalents	¥29.6bn	at 2025-01-20	Cons.	Cash and cash equivalents
Cash & equivalents	¥33.7bn	at 2024-01-20	Cons.	Cash and cash equivalents
Cash & equivalents	¥29.2bn	at 2023-01-20^d	Cons.	Cash and cash equivalents
Cash & equivalents	¥30.1bn	at 2022-01-20^d	Cons.	Cash and cash equivalents (5-year summary)
Cash & equivalents	¥32.7bn	at 2021-01-20^d	Cons.	Cash and cash equivalents (5-year summary)
Operating cash flow	¥10.8bn	2024-01-21 → 2025-01-20	Cons.	Net cash provided by used in operating activities
Operating cash flow	¥9.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in operating activities
Operating cash flow	¥5.1bn	2022-01-21 → 2023-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥8.1bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥12.5bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Investing cash flow	−¥11.6bn	2024-01-21 → 2025-01-20	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥1.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥5.0bn	2022-01-21 → 2023-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥6.5bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥7.6bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Financing cash flow	−¥1.7bn	2024-01-21 → 2025-01-20	Cons.	Net cash provided by used in financing activities
Financing cash flow	−¥3.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in financing activities
Financing cash flow	−¥1.1bn	2022-01-21 → 2023-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	−¥3.7bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	−¥2.3bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
EPS (basic)	¥120.66	2024-01-21 → 2025-01-20	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥140.77	2023-01-21 → 2024-01-20	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-16.2	2022-01-21 → 2023-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥127.1	2021-01-21 → 2022-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥100.66	2020-01-21 → 2021-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
Net assets per share	¥2,908.51	at 2025-01-20	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,843.99	at 2024-01-20	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,663.79	at 2023-01-20^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,645.36	at 2022-01-20^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,612.23	at 2021-01-20^d	Cons.	Net assets per share (5-year summary)
Equity ratio	49.6%	at 2025-01-20	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	50.4%	at 2024-01-20	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	50.9%	at 2023-01-20^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	52.1%	at 2022-01-20^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	51.8%	at 2021-01-20^d	Cons.	Equity to asset ratio (5-year summary)
ROE	4.2%	2024-01-21 → 2025-01-20	Cons.	Rate of return on equity (5-year summary)
ROE	5.1%	2023-01-21 → 2024-01-20	Cons.	Rate of return on equity (5-year summary)
ROE	-0.6%	2022-01-21 → 2023-01-20^d	Cons.	Rate of return on equity (5-year summary)
ROE	4.8%	2021-01-21 → 2022-01-20^d	Cons.	Rate of return on equity (5-year summary)
ROE	3.8%	2020-01-21 → 2021-01-20^d	Cons.	Rate of return on equity (5-year summary)
Employees	5,555	at 2025-01-20	Cons.	Number of employees
Employees	5,182	at 2024-01-20	Cons.	Number of employees
Employees	4,122	at 2023-01-20^d	Cons.	Number of employees
Employees	4,029	at 2022-01-20^d	Cons.	Number of employees
Employees	3,922	at 2021-01-20^d	Cons.	Number of employees
Revenue	¥5.4bn	2024-01-21 → 2025-01-20	Standalone	Operating revenue1
Revenue	¥5.3bn	2023-01-21 → 2024-01-20	Standalone	Operating revenue1
Revenue	¥5.0bn	2022-01-21 → 2023-01-20^d	Standalone	Operating revenue1 (5-year summary)
Revenue	¥4.8bn	2021-01-21 → 2022-01-20^d	Standalone	Operating revenue1 (5-year summary)
Revenue	¥4.8bn	2020-01-21 → 2021-01-20^d	Standalone	Operating revenue1 (5-year summary)
Operating income	¥972m	2024-01-21 → 2025-01-20	Standalone	Operating income
Operating income	¥1.1bn	2023-01-21 → 2024-01-20	Standalone	Operating income
Ordinary income	¥1.4bn	2024-01-21 → 2025-01-20	Standalone	Ordinary income
Ordinary income	¥2.0bn	2023-01-21 → 2024-01-20	Standalone	Ordinary income
Ordinary income	¥2.3bn	2022-01-21 → 2023-01-20^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥2.4bn	2021-01-21 → 2022-01-20^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥1.9bn	2020-01-21 → 2021-01-20^d	Standalone	Ordinary income loss (5-year summary)
Profit before tax	¥4.2bn	2024-01-21 → 2025-01-20	Standalone	Income before income taxes
Profit before tax	¥4.0bn	2023-01-21 → 2024-01-20	Standalone	Income before income taxes
Net income	¥3.1bn	2024-01-21 → 2025-01-20	Standalone	Profit loss
Net income	¥2.9bn	2023-01-21 → 2024-01-20	Standalone	Profit loss
Net income	¥1.9bn	2022-01-21 → 2023-01-20^d	Standalone	Net income loss (5-year summary)
Net income	¥1.4bn	2021-01-21 → 2022-01-20^d	Standalone	Net income loss (5-year summary)
Net income	¥899m	2020-01-21 → 2021-01-20^d	Standalone	Net income loss (5-year summary)
Total assets	¥126.0bn	at 2025-01-20	Standalone	Assets
Total assets	¥124.8bn	at 2024-01-20	Standalone	Assets
Total assets	¥122.7bn	at 2023-01-20^d	Standalone	Total assets (5-year summary)
Total assets	¥122.2bn	at 2022-01-20^d	Standalone	Total assets (5-year summary)
Total assets	¥116.8bn	at 2021-01-20^d	Standalone	Total assets (5-year summary)
Total liabilities	¥43.3bn	at 2025-01-20	Standalone	Liabilities
Total liabilities	¥42.4bn	at 2024-01-20	Standalone	Liabilities
Net assets / equity	¥82.6bn	at 2025-01-20	Standalone	Net assets
Net assets / equity	¥82.4bn	at 2024-01-20	Standalone	Net assets
Net assets / equity	¥80.5bn	at 2023-01-20^d	Standalone	Net assets
Net assets / equity	¥80.1bn	at 2022-01-20^d	Standalone	Net assets (5-year summary)
Net assets / equity	¥78.5bn	at 2021-01-20^d	Standalone	Net assets (5-year summary)
Cash and deposits	¥21.7bn	at 2025-01-20	Standalone	Cash and deposits
Cash and deposits	¥25.8bn	at 2024-01-20	Standalone	Cash and deposits
EPS (basic)	¥98.35	2024-01-21 → 2025-01-20	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥92.22	2023-01-21 → 2024-01-20	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥61.07	2022-01-21 → 2023-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥45.88	2021-01-21 → 2022-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥28.25	2020-01-21 → 2021-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
Dividend per share	¥40	2024-01-21 → 2025-01-20	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2023-01-21 → 2024-01-20	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2022-01-21 → 2023-01-20^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2021-01-21 → 2022-01-20^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2020-01-21 → 2021-01-20^d	Standalone	Dividend paid per share (5-year summary)
Net assets per share	¥2,614.69	at 2025-01-20	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,618.07	at 2024-01-20	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,564.03	at 2023-01-20^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,559.09	at 2022-01-20^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,512.97	at 2021-01-20^d	Standalone	Net assets per share (5-year summary)
Equity ratio	65.6%	at 2025-01-20	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	66.0%	at 2024-01-20	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	65.6%	at 2023-01-20^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	65.6%	at 2022-01-20^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	67.2%	at 2021-01-20^d	Standalone	Equity to asset ratio (5-year summary)
ROE	3.8%	2024-01-21 → 2025-01-20	Standalone	Rate of return on equity (5-year summary)
ROE	3.6%	2023-01-21 → 2024-01-20	Standalone	Rate of return on equity (5-year summary)
ROE	2.4%	2022-01-21 → 2023-01-20^d	Standalone	Rate of return on equity (5-year summary)
ROE	1.8%	2021-01-21 → 2022-01-20^d	Standalone	Rate of return on equity (5-year summary)
ROE	1.1%	2020-01-21 → 2021-01-20^d	Standalone	Rate of return on equity (5-year summary)
Shares issued	33,137,000	at 2025-01-20	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2024-01-20	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2023-01-20^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2022-01-20^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2021-01-20^d	Standalone	Total number of issued shares (5-year summary)
Employees	51	at 2025-01-20	Standalone	Number of employees
Employees	39	at 2024-01-20	Standalone	Number of employees
Employees	26	at 2023-01-20^d	Standalone	Number of employees
Employees	23	at 2022-01-20^d	Standalone	Number of employees
Employees	19	at 2021-01-20^d	Standalone	Number of employees

Periods use the dates stated in the filing. ^d = earlier-year period dated by calendar; ^v = that date confirmed by the company's own earlier filing.

Segments · 95

Segment	Item	Period	Value
Reconciling Itemsreconciling	capex	2024-01-21 → 2025-01-20	¥597m
Reconciling Itemsreconciling	depreciation	2024-01-21 → 2025-01-20	¥796m
Reconciling Itemsreconciling	revenue	2024-01-21 → 2025-01-20	−¥378m
Reconciling Itemsreconciling	revenue intersegment	2024-01-21 → 2025-01-20	−¥378m
Reconciling Itemsreconciling	segment assets	at 2025-01-20	¥34.5bn
Reconciling Itemsreconciling	segment profit	2024-01-21 → 2025-01-20	−¥2.1bn
Domestic Beverage Businessreportable segment	capex	2024-01-21 → 2025-01-20	¥7.1bn
Domestic Beverage Businessreportable segment	depreciation	2024-01-21 → 2025-01-20	¥5.6bn
Domestic Beverage Businessreportable segment	employees	at 2025-01-20	3676 pure
Domestic Beverage Businessreportable segment	revenue	2024-01-21 → 2025-01-20	¥147.5bn
Domestic Beverage Businessreportable segment	revenue external	2024-01-21 → 2025-01-20	¥147.4bn
Domestic Beverage Businessreportable segment	revenue intersegment	2024-01-21 → 2025-01-20	¥86m
Domestic Beverage Businessreportable segment	segment assets	at 2025-01-20	¥74.8bn
Domestic Beverage Businessreportable segment	segment profit	2024-01-21 → 2025-01-20	¥986m
Dy Do Pharmareportable segment	capex	2024-01-21 → 2025-01-20	¥382m
Dy Do Pharmareportable segment	depreciation	2024-01-21 → 2025-01-20	¥21m
Dy Do Pharmareportable segment	employees	at 2025-01-20	12 pure
Dy Do Pharmareportable segment	revenue	2024-01-21 → 2025-01-20	¥8m
Dy Do Pharmareportable segment	revenue external	2024-01-21 → 2025-01-20	¥8m
Dy Do Pharmareportable segment	segment assets	at 2025-01-20	¥780m
Dy Do Pharmareportable segment	segment profit	2024-01-21 → 2025-01-20	−¥621m
Food Businessreportable segment	capex	2024-01-21 → 2025-01-20	¥1.2bn
Food Businessreportable segment	depreciation	2024-01-21 → 2025-01-20	¥834m
Food Businessreportable segment	employees	at 2025-01-20	309 pure
Food Businessreportable segment	revenue	2024-01-21 → 2025-01-20	¥20.7bn
Food Businessreportable segment	revenue external	2024-01-21 → 2025-01-20	¥20.6bn
Food Businessreportable segment	revenue intersegment	2024-01-21 → 2025-01-20	¥7m
Food Businessreportable segment	segment assets	at 2025-01-20	¥21.0bn
Food Businessreportable segment	segment profit	2024-01-21 → 2025-01-20	¥1.2bn
International Beverage Businessreportable segment	capex	2024-01-21 → 2025-01-20	¥9.0bn
International Beverage Businessreportable segment	depreciation	2024-01-21 → 2025-01-20	¥1.9bn
International Beverage Businessreportable segment	employees	at 2025-01-20	1148 pure
International Beverage Businessreportable segment	revenue	2024-01-21 → 2025-01-20	¥56.3bn
International Beverage Businessreportable segment	revenue external	2024-01-21 → 2025-01-20	¥56.3bn
International Beverage Businessreportable segment	segment assets	at 2025-01-20	¥37.5bn
International Beverage Businessreportable segment	segment profit	2024-01-21 → 2025-01-20	¥5.1bn
Pharmaceutical Related Businessreportable segment	capex	2024-01-21 → 2025-01-20	¥576m
Pharmaceutical Related Businessreportable segment	depreciation	2024-01-21 → 2025-01-20	¥1.4bn
Pharmaceutical Related Businessreportable segment	employees	at 2025-01-20	359 pure
Pharmaceutical Related Businessreportable segment	revenue	2024-01-21 → 2025-01-20	¥13.1bn
Pharmaceutical Related Businessreportable segment	revenue external	2024-01-21 → 2025-01-20	¥12.8bn
Pharmaceutical Related Businessreportable segment	revenue intersegment	2024-01-21 → 2025-01-20	¥284m
Pharmaceutical Related Businessreportable segment	segment assets	at 2025-01-20	¥16.6bn
Pharmaceutical Related Businessreportable segment	segment profit	2024-01-21 → 2025-01-20	¥277m
—segment total	capex	2024-01-21 → 2025-01-20	¥18.2bn
—segment total	depreciation	2024-01-21 → 2025-01-20	¥9.7bn
—segment total	revenue	2024-01-21 → 2025-01-20	¥237.6bn
—segment total	revenue external	2024-01-21 → 2025-01-20	¥237.2bn
—segment total	revenue intersegment	2024-01-21 → 2025-01-20	¥378m
—segment total	segment assets	at 2025-01-20	¥150.8bn
—segment total	segment profit	2024-01-21 → 2025-01-20	¥6.9bn
Reconciling Itemsreconciling	capex	2023-01-21 → 2024-01-20	¥926m
Reconciling Itemsreconciling	depreciation	2023-01-21 → 2024-01-20	¥793m
Reconciling Itemsreconciling	revenue	2023-01-21 → 2024-01-20	−¥366m
Reconciling Itemsreconciling	revenue intersegment	2023-01-21 → 2024-01-20	−¥366m
Reconciling Itemsreconciling	segment assets	at 2024-01-20	¥44.8bn
Reconciling Itemsreconciling	segment profit	2023-01-21 → 2024-01-20	−¥2.2bn
Domestic Beverage Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥9.4bn
Domestic Beverage Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥5.1bn
Domestic Beverage Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥153.6bn
Domestic Beverage Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥153.6bn
Domestic Beverage Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥26m
Domestic Beverage Businessreportable segment	segment assets	at 2024-01-20	¥74.7bn
Domestic Beverage Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥4.3bn
Dy Do Pharmareportable segment	capex	2023-01-21 → 2024-01-20	¥57m
Dy Do Pharmareportable segment	depreciation	2023-01-21 → 2024-01-20	¥9m
Dy Do Pharmareportable segment	segment assets	at 2024-01-20	¥381m
Dy Do Pharmareportable segment	segment profit	2023-01-21 → 2024-01-20	−¥796m
Food Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥638m
Food Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥848m
Food Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥20.7bn
Food Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥20.7bn
Food Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥7m
Food Businessreportable segment	segment assets	at 2024-01-20	¥21.4bn
Food Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥993m
International Beverage Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥1.2bn
International Beverage Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥859m
International Beverage Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥26.4bn
International Beverage Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥26.4bn
International Beverage Businessreportable segment	segment assets	at 2024-01-20	¥16.7bn
International Beverage Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥1.1bn
Pharmaceutical Related Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥483m
Pharmaceutical Related Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥1.2bn
Pharmaceutical Related Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥13.0bn
Pharmaceutical Related Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥12.6bn
Pharmaceutical Related Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥331m
Pharmaceutical Related Businessreportable segment	segment assets	at 2024-01-20	¥19.5bn
Pharmaceutical Related Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥367m
—segment total	capex	2023-01-21 → 2024-01-20	¥11.7bn
—segment total	depreciation	2023-01-21 → 2024-01-20	¥8.0bn
—segment total	revenue	2023-01-21 → 2024-01-20	¥213.7bn
—segment total	revenue external	2023-01-21 → 2024-01-20	¥213.4bn
—segment total	revenue intersegment	2023-01-21 → 2024-01-20	¥366m
—segment total	segment assets	at 2024-01-20	¥132.7bn
—segment total	segment profit	2023-01-21 → 2024-01-20	¥5.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,765

Item	Context	Value	Unit
Insurance proceeds inv cf	Prior1YearDuration	864000000	JPY
Insurance proceeds inv cf	CurrentYearDuration	－	JPY
Other net inv cf	Prior1YearDuration	-38000000	JPY
Other net inv cf	CurrentYearDuration	-99000000	JPY
Net cash provided by used in investment activities	Prior1YearDuration	-1240000000	JPY
Net cash provided by used in investment activities	CurrentYearDuration	-11595000000	JPY
Increase in short term loans payable fin cf	Prior1YearDuration	141000000	JPY
Increase in short term loans payable fin cf	CurrentYearDuration	50000000	JPY
Decrease in short term loans payable fin cf	Prior1YearDuration	-100000000	JPY
Decrease in short term loans payable fin cf	CurrentYearDuration	-91000000	JPY
Proceeds from long term loans payable fin cf	Prior1YearDuration	3000000000	JPY
Proceeds from long term loans payable fin cf	CurrentYearDuration	5359000000	JPY
Repayment of long term loans payable fin cf	Prior1YearDuration	-4414000000	JPY
Repayment of long term loans payable fin cf	CurrentYearDuration	-5119000000	JPY
Repayments of lease obligations fin cf	Prior1YearDuration	-1039000000	JPY
Repayments of lease obligations fin cf	CurrentYearDuration	-1201000000	JPY
Cash dividends paid fin cf	Prior1YearDuration	-953000000	JPY
Cash dividends paid fin cf	CurrentYearDuration	-954000000	JPY
Dividends paid to non controlling interests fin cf	Prior1YearDuration	－	JPY
Dividends paid to non controlling interests fin cf	CurrentYearDuration	-2000000	JPY
Purchase of treasury stock fin cf	Prior1YearDuration	-0	JPY
Purchase of treasury stock fin cf	CurrentYearDuration	-0	JPY
Proceeds from sales of treasury stock fin cf	Prior1YearDuration	153000000	JPY
Proceeds from sales of treasury stock fin cf	CurrentYearDuration	251000000	JPY
Net cash provided by used in financing activities	Prior1YearDuration	-3212000000	JPY
Net cash provided by used in financing activities	CurrentYearDuration	-1708000000	JPY
Effect of exchange rate change on cash and cash equivalents	Prior1YearDuration	-201000000	JPY
Effect of exchange rate change on cash and cash equivalents	CurrentYearDuration	-1592000000	JPY
Net increase decrease in cash and cash equivalents	Prior1YearDuration	4557000000	JPY
Net increase decrease in cash and cash equivalents	CurrentYearDuration	-4071000000	JPY
Cash and cash equivalents	Prior2YearInstant	29156000000	JPY
Cash and cash equivalents	Prior1YearInstant	33713000000	JPY
Cash and cash equivalents	Prior1YearInstant	33713000000	JPY
Cash and cash equivalents	CurrentYearInstant	29642000000	JPY
Number of consolidated subsidiaries	CurrentYearInstant	21
Number of associates accounted for using equity method	CurrentYearInstant	6
Accumulated depreciation ppe by group	Prior1YearInstant	-87838000000	JPY
Accumulated depreciation ppe by group	CurrentYearInstant	-101035000000	JPY
Notes receivable trade	Prior1YearInstant	379000000	JPY
Notes receivable trade	CurrentYearInstant	329000000	JPY
Accounts receivable trade	Prior1YearInstant	21811000000	JPY
Accounts receivable trade	CurrentYearInstant	26057000000	JPY
Promotion expenses sga	Prior1YearDuration	24822000000	JPY
Promotion expenses sga	CurrentYearDuration	25127000000	JPY
Salaries and allowances sga	Prior1YearDuration	18380000000	JPY
Salaries and allowances sga	CurrentYearDuration	19284000000	JPY
Shipment and delivery expenses sga	Prior1YearDuration	8830000000	JPY
Shipment and delivery expenses sga	CurrentYearDuration	11812000000	JPY
Provision for bonuses sga	Prior1YearDuration	1302000000	JPY
Provision for bonuses sga	CurrentYearDuration	1389000000	JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed

balance sheet identity	consolidated 2024-01-20	pass rounding
balance sheet identity	consolidated 2025-01-20	pass rounding
balance sheet identity	non_consolidated 2024-01-20	pass rounding
balance sheet identity	non_consolidated 2025-01-20	pass
dei present		pass
period resolution		pass
statement vs summary · net assets	consolidated 2023-01-20	pass
statement vs summary · net assets	consolidated 2024-01-20	pass
statement vs summary · net assets	consolidated 2025-01-20	pass
statement vs summary · net assets	non_consolidated 2023-01-20	pass
statement vs summary · net assets	non_consolidated 2024-01-20	pass
statement vs summary · net assets	non_consolidated 2025-01-20	pass
statement vs summary · net income attributable to parent	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · net income attributable to parent	consolidated 2024-01-21/2025-01-20	pass
statement vs summary · operating cash flow	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · operating cash flow	consolidated 2024-01-21/2025-01-20	pass
statement vs summary · revenue	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · revenue	consolidated 2024-01-21/2025-01-20	pass
statement vs summary · revenue	non_consolidated 2023-01-21/2024-01-20	pass
statement vs summary · revenue	non_consolidated 2024-01-21/2025-01-20	pass
statement vs summary · total assets	consolidated 2024-01-20	pass
statement vs summary · total assets	consolidated 2025-01-20	pass
statement vs summary · total assets	non_consolidated 2024-01-20	pass
statement vs summary · total assets	non_consolidated 2025-01-20	pass